Stock Market & Financial Investment News

Curis shares should be bought on weakness, says Roth CapitalRoth Capital believes that the recent weakness in Curis was caused by statements from a physician who inaccurately described the resistance rates of Curis' Erivedge. The firm reiterates a $9 price target and Buy rating on the shares.